Roche dishes out $7.1B for Roivant-Pfizer IBD drug in anti-TL1A sprintnews2023-10-23T06:54:12+00:00October 23rd, 2023|Endpoints News|
Roche details Alecensa data that may shift the drug to postsurgery ALK-positive lung cancer: #ESMO23news2023-10-23T06:21:10+00:00October 23rd, 2023|Endpoints News|
Padcev-Keytruda combo sets new standard of care in bladder cancer at ESMOnews2023-10-23T05:30:25+00:00October 23rd, 2023|Endpoints News|
CARGO Therapeutics files for IPO, aiming to raise money to fund cell therapy ambitionsnews2023-10-21T12:38:47+00:00October 21st, 2023|Endpoints News|
Icahn lawsuit asks for millions in damages, removal of Illumina board membersnews2023-10-21T12:20:50+00:00October 21st, 2023|Endpoints News|
Merck’s big ADC move; Latest from #ESMO23; How Eli Lilly is thinking about deals; AI-designed drugs face reckoning in clinic; and morenews2023-10-21T10:00:13+00:00October 21st, 2023|Endpoints News|
Eli Lilly reveals two-year data for experimental eczema treatment after FDA roadblocknews2023-10-20T19:56:11+00:00October 20th, 2023|Endpoints News|
A first for the European Commission: Five pharma companies fined $14M for API price fixingnews2023-10-20T19:43:53+00:00October 20th, 2023|Endpoints News|
Pfizer wins first US approval for pentavalent meningococcal vaccine news2023-10-20T19:42:29+00:00October 20th, 2023|Endpoints News|
House Republicans threaten subpoena over details of NIH mpox researchnews2023-10-20T19:42:27+00:00October 20th, 2023|Endpoints News|
